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Abstract
Bicuspid aortic valve (BAV) is the most common type of cardiac malformation
with an estimated prevalence of 1 % in the population. BAV results in significant
morbidity usually during adulthood due to its association with aortic valve
calcification and ascending aortic aneurysms. Mutations in the signaling and
transcriptional regulator, NOTCH1, are a cause of bicuspid aortic valve in
non-syndromic autosomal dominant human pedigrees. The Notch signaling
pathway is critical for multiple cellular processes during both development
and disease and is expressed in the developing and adult aortic valve consistent
with the cardiac phenotypes identified in affected family members. Recent work
has begun to elucidate the molecular mechanisms underlying the link between
Notch1 signaling and the development of BAV and valve calcification. Using
in vitro approaches, loss of Notch signaling has been shown to contribute to
aortic valve calcification via Runx2-, Sox9-, and Bmp2-dependent mechanisms.
In addition, Notch1 signaling has been shown to be responsive to nitric oxide
signaling during this disease process. A new highly penetrant mouse model of
aortic valve disease using Notch1 haploinsufficient mice that are backcrossed in
an endothelial nitric oxide synthase (Nos3)-null background was generated.
Notch1 and Nos3 compound mutant mice (Notch1þ/-;Nos3-/-) display a nearly
100 % incidence of aortic valve malformations, most commonly BAV. The
aortic valves of adult mutant mice are thickened and have associated stenosis
and regurgitation. Based upon the initial discovery of NOTCH1 mutations in
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humans with aortic valve disease, subsequent studies have provided significant
molecular insights into BAV-associated diseases.
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53.1 Introduction
Congenital heart disease (CHD) is the most common type of birth defect, with an
estimated incidence that ranges from 6 to 19 per 1,000 live births [1]. Even with
recent improvements in the care of children, CHD remains a leading cause of infant
mortality [2]. The etiology for the majority of cases of CHD remains unknown
despite advances in cardiac developmental biology and genetics [3]. While the role
of nongenetic causes, such as infectious agents and teratogens, appears to play a
causative role in a minority of cases CHD, the role of genetic factors in CHD has
become an area of robust investigation. Numerous etiologic genes for CHD have
been identified using conventional linkage or candidate gene sequencing
approaches and more recently using array-based methodologies or whole exome/
genome sequencing [4].
Within CHD, bicuspid aortic valve (BAV) is the most common congenital
cardiac malformation with an estimated prevalence of 1 % in the population.
BAV occurs when the aortic valve has only two cusps instead of the normal three
[5]. BAV is a common cause of adult valve disease as it is often asymptomatic
during childhood. With BAV, the normally thin aortic valve cusps often prema-
turely calcify leading to valvar thickening and stenosis [5]. BAV may also present
with aortic regurgitation and affected individuals are at increased risk for infective
endocarditis. BAV is also associated with ascending aortic dilation/aneurysm and
may result in the development of aortic dissection [5].
Since early case reports described families with multiple members with BAV
nearly four decades ago, several population-based studies have demonstrated a
strong genetic component in BAV. This chapter will review how the identification
of mutations in NOTCH1 in families with inherited BAV have led to an increased
understanding of the role of Notch signaling in aortic valve calcification and the
generation of novel mouse model of BAV with associated valve disease.
53.2 NOTCH1 Mutations and Aortic Valve Disease
We reported a novel genetic etiology of non-syndromic BAV in humans in 2005
[6]. Using a positional cloning approach, a large family with 11 members affected
with autosomal dominant aortic valve disease was studied. The primary cardiac
malformation in affected family members was BAV. Seven members had
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developed calcification of the aortic valve including four who required surgical
valve replacement. The disease locus was mapped to chromosome 9q34, and
subsequent sequencing of a candidate gene, NOTCH1, identified a nonsense muta-
tion in affected family members. In a smaller unrelated family, a NOTCH1 frame-
shift mutation segregated with a similar aortic valve phenotype. Observations of
missense NOTCH1mutations in a subset (~5 %) of individuals with BAV have also
been reported with supporting functional data indicating impaired Notch signaling
[7, 8]. These publications suggested that NOTCH1 haploinsufficiency was a cause
of BAV in humans.
NOTCH1 encodes a single-pass transmembrane receptor and functions in a
highly conserved pathway, which plays critical roles in cell fate determination
during organogenesis. In mammals, there are four NOTCH receptors (NOTCH1-
4), and they interact with two families of ligands (Jagged 1 and 2 and Delta 1, 3, and
4) [9]. Other Notch family members have been linked to human disease as hetero-
zygous mutations in NOTCH3 have been identified in CADASIL syndrome, while
mutations in JAGGED1 and NOTCH2 are found in Alagille syndrome. Targeted
disruption of Notch1 in mice results in embryonic lethality secondary to vascular
defects prior to cardiac valvulogenesis [10]. Each Notch family member has a
distinct expression pattern, and Notch1 is expressed not only in the endocardium
but also the outflow tract cushion mesenchyme during development consistent with
the valve phenotype seen in the affected family members [6, 11]. In addition,
Notch1 mRNA transcripts are found in the adult murine aortic valve. These findings
suggest that Notch1 signaling is important for aortic valve formation and poten-
tially in adult valve diseases.
53.3 Notch1 Signaling and Aortic Valve Calcification
With the increased longevity of human population, calcific valvular disease is
becoming more prevalent. Calcific aortic stenosis affects an estimated 2–3 % of
the population by 65 years of age [12]. Calcification of the normally thin aortic
valve cusps leads to valvular thickening with resultant stenosis/regurgitation that
ultimately requires surgical replacement. Examination of calcified human valves
has demonstrated increased expression of osteogenic markers such as Runx2
[12]. The process of valvular calcification was traditionally proposed to be a
degenerative process that occurred with aging, but increasing evidence suggests
that molecular pathways underlie this complex disease [12]. In addition to clinical
risk factors such as hypertension and hypercholesterolemia, BAV is a major risk
factor for CAVD.
The role of the Notch signaling pathway in the development of CAVD has
becoming increasingly recognized. Our initial studies demonstrated that Notch1
repressed the activity of Runx2, a transcriptional regulator of osteoblast cell fate
[6]. Subsequently our studies focused on the molecular changes that occur with
inhibition of Notch signaling in the aortic valve [11]. Consistent with this hypothe-
sis, diseased human aortic valves have decreased expression of NOTCH1 in areas
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of calcium deposition. To identify downstream mediators of Notch1 during valve
calcification, the gene expression changes that occur with chemical inhibition of
Notch signaling in rat aortic valve interstitial cells (AVICs) were studied.
Downregulation of Sox9 along with several cartilage-specific genes that were direct
targets of this transcription factor was identified. Loss of Sox9 has been published
to be associated with aortic valve calcification in mouse models [13]. Utilizing an
in vitro porcine aortic valve calcification model system, inhibition of Notch activity
resulted in accelerated calcification, while stimulation of Notch signaling
attenuated the calcific process. Overexpression of Sox9 was able to prevent the
calcification of porcine AVICs that occurs with Notch inhibition. These studies
demonstrated that loss of Notch signaling contributes to aortic valve calcification
via a Sox9-dependent mechanism. Additional work by other investigators has
supported these conclusions and have also demonstrated a role for Bmp2 as a
downstream target of Notch1 signaling in this process and found that Notch1
haploinsufficient mice develop aortic valve calcification with aging [14, 15].
Dysfunction of the valvular endothelium is thought to initiate calcification of
neighboring AVICs leading to CAVD. The molecular mechanism by which endo-
thelial cells communicate with AVICs and cause disease is not well understood.
Using a coculture and transwell assays, it was shown that a secreted signal from
endothelial cells inhibits calcification of porcine AVICs [16]. Nitric oxide (NO),
which is secreted by endothelial cells, is critical for numerous physiologic and
pathologic processes and had been implicated in the process of aortic valve calcifi-
cation. In addition, mice lacking Nos3, which encodes for endothelial nitric oxide
synthase, display partially penetrant BAV and making NO a potential candidate for
this secreted signal. NO prevents calcification of AVICs in vitro, similar to the
presence of endothelial cells, while the absence of NO increases calcification.
Overexpression of a constitutively active Notch1 in AVICs prevented calcification
that occurs with NO inhibition linking NO and Notch signaling in this process.
Consistent with this, endothelial-derived NO signaling increases the expression of a
Notch signaling target genes in AVICs and inhibition of NO decreased nuclear
localization of NICD in AVICs. Conversely, increased nuclear localization of
NICD was noted with the addition of NO donor. Lastly, the NOS3 and Notch1
signaling pathways genetically interact in vivo as NOS3;Notch1 compound mutant
mice display a highly penetrant aortic valve disease [16]. These mice have highly
penetrant BAV and develop hemodynamically significant aortic valve stenosis and
regurgitation. These studies suggest that NO signaling in valve endothelial cells
regulates Notch1, Sox9, and Bmp2 in the neighboring AVICs and this pathway may
be critical in the pathogenesis of adult-onset aortic valve calcification (Fig. 53.1).
53.4 Future Directions and Clinical Implications
While mutations in NOTCH1 were identified in a family with a common cardiac
valve malformation, subsequent work has demonstrated a role for Notch1 in aortic
valve calcification. The development of a highly penetrant mouse model of BAV
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will assist in the dissection of the molecular pathways that lead to the development
of this common cardiac malformation. Interestingly, mice deficient for Gata5
display partially penetrant BAV and have reduced expression of Nos3 and Notch
signaling [17]. These mice also offer an opportunity to study the development of
BAV-associated ascending aortic aneurysms. Future investigations into the down-
stream targets of Notch1 signaling may lead to novel therapies for BAV-associated
diseases such as CAVD.
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